Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
暂无分享，去创建一个
M. Ducreux | H. Chang | E. Chen | J. Harding | M. Tejani | J. Bridgewater | J. W. Kim | H. Wasan | J. Metges | D. Oh | D. Kim | T. Macarulla | J. Ying | S. Pant | P. Garfin | Y. Bao | Hui-Chuan Sun | Lisa Boyken | J. Fan | Hye Jin Choi | Lequn Bao | F. Xie | Myung-Ah Lee | Jiafang Ma | L. Boyken | Jia Fan